Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

North America Cystic Fibrosis Therapeutics Market Forecast 2020-2028

Published by Inkwood Research Product code 927064
Published Content info 112 Pages
Delivery time: 2-3 business days
Price
Back to Top
North America Cystic Fibrosis Therapeutics Market Forecast 2020-2028
Published: March 2, 2020 Content info: 112 Pages
Description

KEY FINDINGS

The North America cystic fibrosis therapeutics market is estimated to register a CAGR of 10.07% over the projected period of 2020-2028. The market in North America is mainly driven by the presence of significant players in the biotechnology industry such as Vertex Pharmaceuticals Incorporated, Mylan N.V., and many others, who are investing mostly for the development of new technologies that can be used in the advancement of new testing techniques and improvement of the existing ones.

MARKET INSIGHTS

The cystic fibrosis therapeutics market of North America is segmented into the United States and Canada for further surveying growth in the region. In Canada, cystic fibrosis is the most common lethal hereditary disease affecting children and adolescents. It is calculated that out of every 3,600 children, one child has CF in Canada. The estimates show that the number of children, adolescents, and adults, with cystic fibrosis, attending specialized CF clinics, is more than 4,100, and approximately one in 25 Canadians carry an abnormal version of the gene responsible for causing cystic fibrosis. Canada is one of the emerging countries in North America, which holds approximately 11% share in the North American cystic fibrosis therapeutics market.

Further, Canada is one of the largest economies in the world, and its high healthcare expenditure, with universal healthcare sponsored through taxes, is among the best across the globe. Hence, increasing healthcare spending, along with the prevalence of this disease, is estimated to drive market growth. The market constraints in the North American region include monetary obstacles owing to the high cost of technology production.

COMPETITIVE INSIGHTS

AbbVie Inc, Abbott Laboratories, Agilent Technologies, Inc, Johnson & Johnson, Gilead Sciences, Inc, etc. are some of the renowned companies operating in the market.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 29837

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
    • 3.2.2. INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
    • 3.2.3. RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. STRINGENT REGULATION
    • 3.3.2. LOW AWARENESS AMONG DEVELOPING ECONOMIES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. PESTEL ANALYSIS
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY ROUTE OF ADMINISTRATION

  • 5.1. INHALE
  • 5.2. ORAL

6. MARKET BY DRUG CLASS

  • 6.1. CFTR MODULATORS
  • 6.2. BRONCHODILATORS
  • 6.3. MUCOLYTIC
  • 6.4. PANCREATIC ENZYME SUPPLEMENTS

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA

8. COMPANY PROFILES

  • 8.1. ABBOTT LABORATORIES
  • 8.2. ABBVIE INC
  • 8.3. AGILENT TECHNOLOGIES INC
  • 8.4. ALLERGAN PLC
  • 8.5. F. HOFFMANN-LA ROCHE
  • 8.6. GILEAD SCIENCES INC
  • 8.7. GLAXOSMITHKLINE PLC
  • 8.8. JOHNSON & JOHNSON
  • 8.9. MYLAN N.V
  • 8.10. NOVARTIS AG
  • 8.11. PERKINELMER
  • 8.12. PFIZER INC
  • 8.13. PHARMAXIS LTD
  • 8.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 8.15. VERTEX PHARMACEUTICALS INCORPORATED

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - VETERINARY VACCINE
  • TABLE 2: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: NORTH AMERICA INHALE MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: NORTH AMERICA INHALE MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: NORTH AMERICA ORAL MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: NORTH AMERICA ORAL MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: NORTH AMERICA CFTR MODULATORS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: LIST OF CFTR MODULATORS GENERIC AND BRAND NAME
  • TABLE 12: NORTH AMERICA CFTR MODULATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 13: NORTH AMERICA BRONCHODILATORS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 14: LIST OF BRONCHODILATORS GENERIC AND BRAND NAME
  • TABLE 15: NORTH AMERICA BRONCHODILATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: NORTH AMERICA MUCOLYTIC MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: LIST OF MUCOLYTICS GENERIC AND BRAND NAME
  • TABLE 18: NORTH AMERICA MUCOLYTIC MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 19: NORTH AMERICA PANCREATIC ENZYME SUPPLEMENTS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 20: NORTH AMERICA PANCREATIC ENZYME SUPPLEMENTS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 21: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 22: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, IN 2019
  • FIGURE 6: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY INHALE, 2020-2028 (IN $ MILLION)
  • FIGURE 7: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ORAL, 2020-2028 (IN $ MILLION)
  • FIGURE 8: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, IN 2019
  • FIGURE 9: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY CFTR MODULATORS, 2020-2028 (IN $ MILLION)
  • FIGURE 10: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY BRONCHODILATORS, 2020-2028 (IN $ MILLION)
  • FIGURE 11: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY MUCOLYTIC, 2020-2028 (IN $ MILLION)
  • FIGURE 12: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY PANCREATIC ENZYME SUPPLEMENTS, 2020-2028 (IN $ MILLION)
  • FIGURE 13: NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 14: THE UNITED STATES CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 15: CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
Back to Top